GE HealthCare Expands Breast Imaging Portfolio with New ABUS Solutions

GE HealthCare is expanding its diagnostic imaging portfolio with the release of the Invenia ABUS Prime system and the ABUS StreamVue enterprise viewer. These updated platforms are engineered to provide supplemental screening capabilities for patients with dense breast tissue while enabling healthcare networks to utilize browser-based, remote review architectures.

The collaboration with Candelis, Inc. integrates automated ultrasound technology with zero-footprint web viewing systems to improve multi-site diagnostic workflows. This deployment targets high-volume breast centers and enterprise imaging networks within the radiology and oncology sectors.

Automated Ultrasound Diagnostics in Dense Breast Screening
Clinical data indicates that approximately 40% of women possess dense breast tissue, a physiological factor that increases breast cancer risk by a factor of four to six. High tissue density obscures lesions on standard mammography, resulting in up to one-third of cancers being missed during primary screening. Automated breast ultrasound serves as an adjunctive modality to address this diagnostic gap. Following an initial presentation at the Society of Breast Imaging Annual Symposium, the updated ultrasound framework is designed to generate reproducible three-dimensional imaging independent of the operator, delivering standardized data across dispersed enterprise imaging networks.

Artificial Intelligence Integration and Image Acquisition Efficiency
The core diagnostic unit incorporates the cSound Imageformer and Verisound artificial intelligence tools, including automated scan quality assessment and nipple detection mechanisms. A modified acquisition protocol increases scanning speed by up to 40%. The system utilizes a reverse curve transducer with selectable compression settings to optimize tissue contact and standardize the imaging process. Image interpretation is supported by the QVCAD artificial intelligence assistant, which clinical testing indicates reduces reading time by 33% while achieving up to 93% sensitivity for lesion detection.

Browser-Based Remote Reading and Enterprise Deployment
To address distributed diagnostic environments, GE HealthCare collaborated with Candelis, Inc. to engineer ABUS StreamVue, an FDA 510(k)-cleared and CE-marked web viewer. This architecture allows radiologists to access large ultrasound datasets without localized software installation. According to Russ Behler, Global Product Director for LOGIQ Ultrasound at GE HealthCare, the platform extends the value of the ultrasound infrastructure by providing a flexible reading experience that supports remote review, standardized presentation, and simplified deployment across care settings. Initial implementation includes deployment at BeSound, a specialized breast imaging facility in Los Angeles, which utilizes the hardware to expand supplemental screening capacity and plans to equip mobile diagnostic units.

Additional Context:
This section details technical specifications and competitive benchmarking not included in the original product announcement

Automated breast ultrasound systems compete primarily with handheld ultrasound devices and other automated volume scanners within the diagnostic imaging market. Compared to standard handheld ultrasound, which relies heavily on operator technique and positioning, automated systems standardize image acquisition by sweeping a wide-field transducer across the tissue. Competing platforms, such as the Siemens Healthineers ACUSON S2000 Automated Breast Volume Scanner, utilize flat, high-frequency linear arrays for volume acquisition, whereas the GE HealthCare architecture employs a proprietary reverse-curve transducer designed to match patient anatomy. Benchmark criteria for these systems generally evaluate volumetric acquisition speed, field of view, and integration with artificial intelligence for computer-aided detection. Standard mammography remains the primary screening tool, but benchmark comparisons for dense breast evaluation frequently measure the supplemental cancer detection rate, where automated ultrasound typically yields an additional two to four detected malignancies per thousand women screened compared to mammography alone.

Edited by Natania Lyngdoh, Induportals editor, assisted by AI.

www.gehealthcare.com